Knowledgepie develops an iron nanoparticle-based MRI contrast agent that enhances cancer detection and therapy while eliminating the risk of nephrogenic systemic fibrosis associated with traditional gadolinium-based agents. This environmentally friendly solution offers improved diagnostic precision and safety for patients, facilitating the transition from research to clinical application in oncology.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional gadolinium-based MRI contrast agents carry the risk of nephrogenic systemic fibrosis (NSF), particularly for patients with renal impairment. These agents also raise environmental concerns due to the toxicity of gadolinium.
Solution
Knowledgepie develops an iron nanoparticle-based MRI contrast agent as a safer and more environmentally friendly alternative to gadolinium-based agents. The nanoparticle formulation enhances contrast in MRI scans, improving the detection and characterization of tumors. The agent is synthesized through a green route using biocompatible molecules like ascorbic acid and citric acid, resulting in a stable aqueous solution that is non-toxic to normal cells but demonstrates cytotoxicity against tumor cells. This approach aims to provide comparable or advanced functionalities for simultaneous diagnosis and therapy while eliminating the risk of NSF.
Target Audience
The primary target audience includes radiologists, oncologists, and medical professionals requiring MRI contrast agents for tumor detection and characterization, particularly those seeking safer alternatives for patients with renal issues.
Features
- Iron-based nanoparticle contrast agent for MRI.
- Environmentally friendly synthesis using a green route.
- Biocompatible capping molecules (ascorbic acid and citric acid) for stability and reduced toxicity.
- Demonstrated cytotoxicity against tumor cells.
- Potential for simultaneous diagnosis and therapy (theranostics).
- Suitable for use in patients with renal impairment.